Ebb & Flow

Hunter-Fleming set off to a series B financing to support its neurology efforts, and now the U.K. company finds itself with much more, including a stake in a new company and a foothold in the U.S. The company is expected to announce today a $12 million series B round plus an additional $15 million in a separate financing to establishTrident Pharmaceuticals, a company in Boston that will focus exclusively on developing a portfolio compound as an asthma treatment.

"We were going out to raise funds for the whole portfolio when one of the investors announced that it was interested in also funding a new vehicle to develop our HF1020 compound," CEO Jim Murray told Ebb & Flow. ...